Automate Your Wheel Strategy on ABBV
With Tiblio's Option Bot, you can configure your own wheel strategy including ABBV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABBV
- Rev/Share 33.6591
- Book/Share -1.4667
- PB -153.3967
- Debt/Equity -26.0193
- CurrentRatio 0.7245
- ROIC 0.187
- MktCap 404180250615.0
- FreeCF/Share 11.6078
- PFCF 19.65
- PE 169.2874
- Debt/Assets 0.5134
- DivYield 0.0287
- ROE 4.9875
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ABBV | Scotiabank | -- | Sector Outperform | -- | $280 | Nov. 13, 2025 |
| Downgrade | ABBV | DZ Bank | Buy | Hold | -- | $237 | Nov. 4, 2025 |
| Downgrade | ABBV | Erste Group | Buy | Hold | -- | -- | Oct. 14, 2025 |
| Downgrade | ABBV | HSBC Securities | Buy | Hold | -- | -- | Oct. 1, 2025 |
| Upgrade | ABBV | Berenberg | Hold | Buy | -- | $270 | Sept. 17, 2025 |
| Resumed | ABBV | Piper Sandler | -- | Overweight | -- | $231 | Aug. 12, 2025 |
| Upgrade | ABBV | Daiwa Securities | Neutral | Outperform | -- | $214 | Aug. 7, 2025 |
| Downgrade | ABBV | Citigroup | Buy | Neutral | -- | $205 | May 14, 2025 |
| Initiation | ABBV | Cantor Fitzgerald | -- | Overweight | -- | $210 | April 22, 2025 |
| Resumed | ABBV | BofA Securities | -- | Neutral | -- | $191 | Dec. 10, 2024 |
News
ABBV vs. MRK: Which Drug Giant is a Better Buy Now?
Published: April 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Both ABBV and MRK are leading pharmaceutical companies with strong portfolios in oncology and immunology.
Read More
Final Trades: TJX, Meta, Abbvie and Taiwan Semi
Published: April 11, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV
Published: April 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 11, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cerevel-therapeutics-holdings-inc-lawsuit-submission-form?prid=142536&wire=1 or contact Joseph E. Levi, Esq.
Read More
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
Published: April 11, 2025 by: CNBC
Sentiment: Negative
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Read More
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly (LLY) and AstraZeneca (AZN), but Trump's announcement of a pause on reciprocal tariffs offsets the losses.
Read More
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Read More
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Published: April 09, 2025 by: WSJ
Sentiment: Negative
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Read More
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squibb, Regeneron, Merck, Pfizer, Johnson & Johnson and Amgen, among others, all dropped on Wednesday.
Read More
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.
Read More
AbbVie Stock Rises 16% Year to Date: Time to Buy, Sell or Hold?
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
Read More
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Published: April 01, 2025 by: CNBC
Sentiment: Negative
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Read More
Bernstein's Courtney Breen: Merck, Novo Nordisk, others at high risk from tariffs
Published: April 01, 2025 by: CNBC Television
Sentiment: Negative
Courtney Breen, Bernstein senior analyst, joins CNBC's 'Money Movers' to discuss how to draw the line between tariff risks and company financials in pharmaceuticals, which companies are most at risk, and more.
Read More
Final Trades: PayPal, Meta, Abbvie and Snowflake
Published: March 28, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
5 Large Drug Stocks to Watch as Industry Recovers
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Industry Description
Read More
Only Have $500? 3 No-Brainer Stocks to Buy Right Now
Published: March 18, 2025 by: 24/7 Wall Street
Sentiment: Positive
Forget the old adage “it takes money to make money.
Read More
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Published: March 13, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Calls of the Day: United Airlines, Delta, IBM, Abbvie, Uber
Published: March 12, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
Siri & Glimstad Defeats AbbVie's Motion to Dismiss Illinois GIPA Lawsuit
Published: March 11, 2025 by: Accesswire
Sentiment: Neutral
Call to Action: Join Open Class Action Against AbbVie CHICAGO, IL / ACCESS Newswire / March 11, 2025 / Recently, the Northern District of Illinois denied AbbVie's motion to dismiss a lawsuit alleging that AbbVie violated the Illinois Genetic Information Privacy Act ("GIPA"). In Henry v.
Read More
AbbVie Inc. (ABBV) TD Cowen 45th Annual Health Care Conference (Transcript)
Published: March 05, 2025 by: Seeking Alpha
Sentiment: Neutral
AbbVie Inc. (NYSE:ABBV ) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET Company Participants Scott T. Reents - Executive Vice President and Chief Financial Officer Jeffrey R.
Read More
Here's How to Play AbbVie Stock as it Enters the Obesity Space
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
Read More
AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race
Published: March 03, 2025 by: Benzinga
Sentiment: Positive
On Monday, AbbVie Inc ABBV and Gubra A/S announced a license agreement to develop GUB014295, a long-acting amylin analog for obesity. GUB014295 is currently in a Phase 1 clinical trial.
Read More
AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal
Published: March 03, 2025 by: Investopedia
Sentiment: Neutral
AbbVie (ABBV) has agreed to license a weight-loss drug currently in development from Danish biotech firm Gubra for up to about $2.2 billion, signaling its entry in the obesity treatment market.
Read More
Final Trades: Taiwan Semi, Abbvie, Tradeweb Markets and the IYH
Published: March 03, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin Drug
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
Per the terms of the deal, AbbVie will lead the development and commercialization of the obesity drug developed by Gubra.
Read More
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
Published: February 28, 2025 by: PRNewsWire
Sentiment: Neutral
The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib in adults with giant cell arteritis (GCA)1 The primary endpoint of sustained remission* and key secondary endpoints, including reduction in disease flares, lower cumulative steroid exposure, and complete remission,† were met1 GCA is an autoimmune disease that causes inflammation of the large and medium cranial arteries, resulting in potentially debilitating symptoms2 NORTH CHICAGO, Ill. , Feb. 28, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) …
Read More
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Published: February 27, 2025 by: The Motley Fool
Sentiment: Positive
Imagine being able to buy a machine that would work day after day and year after year to make you money. Now imagine being able to buy several such machines.
Read More
AbbVie to Present at the TD Cowen's 45th Annual Health Care Conference
Published: February 26, 2025 by: PRNewsWire
Sentiment: Neutral
NORTH CHICAGO, Ill. , Feb. 26, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025.
Read More
Why AbbVie Remains A Strong Buy For Long-Term Investors
Published: February 23, 2025 by: Seeking Alpha
Sentiment: Positive
Why AbbVie Remains A Strong Buy For Long-Term Investors
Read More
2 Magnificent Dividend Growth Stocks to Load Up On Right Now
Published: February 20, 2025 by: The Motley Fool
Sentiment: Positive
Dividend stocks have been the backbone of market returns for over a century, contributing roughly two-thirds of total returns since 1900, according to a report by the Hartford Funds. Companies that consistently raise their dividends have been particularly strong performers, thanks to their ability to generate steady revenue growth and strong free cash flows across different market cycles.
Read More
AbbVie Appears Ready To Move Higher
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Positive
AbbVie shares recently rebounded, supported by strong earnings, positive guidance, and a late 2024 dividend increase, indicating the potential for further gains. Despite a $3.5 billion impairment charge from Emraclidine's failure, AbbVie's immunology portfolio, led by Skyrizi and Rinvoq, shows robust growth. AbbVie's diversified portfolio, including drugs from the 2019 Allergan acquisition, continues to mitigate revenue declines from Humira's patent expiration.
Read More
About AbbVie Inc. (ABBV)
- IPO Date 2013-01-02
- Website https://www.abbvie.com
- Industry Drug Manufacturers - General
- CEO Robert A. Michael
- Employees 55000